Two funds walk into a table. Only the numbers talk.
Invesco India Pharma and Healthcare Fund vs Nippon India Taiwan Equity Fund
Pick two or three funds. We’ll tell you in plain words which grew faster, which was calmer, which costs less and what your money would have become. Figures are for the Direct plan, Growth option, where a fund has one.
- AInvesco India Pharma and Healthcare Fund
Invesco Mutual Fund- Sectoral / Thematic Fund
- Direct plan
- Very High Risk
NAV ₹10.58 on 13 Nov 2026
- BNippon India Taiwan Equity Fund
Nippon India Mutual Fund- Sectoral / Thematic Fund
- Direct plan
- Very High Risk
NAV ₹28.76 on 13 Nov 2026
The short version
Who comes out ahead on each measure.
Fell less in a crash
AInvesco India Pharma and Healthcare Fund
At its worst, Invesco India Pharma and Healthcare Fund fell 11.4% from its peak, against 44.8% for Nippon India Taiwan Equity Fund. On ₹1 lakh, that's a dip to ₹55,225 at the bottom for Nippon India Taiwan Equity Fund. Could you have held on?
What your money would have become
The same amount, put into each fund on the same day.
Not enough shared history to chart these funds together yet.
Strengths and watch-outs
Each fund judged against its own category, and against a 5-year SBI FD at 6.05%.
AInvesco India Pharma and Healthcare Fund
- Watch out: Small fund (₹436 Cr), often newer or less tested
- Watch out: Less than 3 years of history, too short to judge
BNippon India Taiwan Equity Fund
- Strength: Ahead of its category: 46.5% a year over 3 years, against a category average of 15%
- Strength: In the top quarter of its category over 3 years (#1 of 139)
- Strength: Beat a 5-year SBI FD: 46.5% a year over 3 years, against 6.05%
- Watch out: Swings more than most funds in its category
All the numbers
The stronger figure in each row is marked Best. Under each return is the fund’s rank in its category and the category average.
| Measure | AInvesco India Pharma and Healthcare Fund | BNippon India Taiwan Equity Fund |
|---|---|---|
| ReturnsHow much the fund grew. Beyond a year, this is per year (annualised). | ||
| 1 yearLast 12 months, the most noisy figure | – | 60.6%#1 of 226 · avg 6.1% |
| 3 yearsPer year, over a full market mood swing | – | 46.5%#1 of 139 · avg 15% |
| RiskHow bumpy the ride was. This is what decides whether you stay invested. | ||
| Ups and downsVolatility: how far it swings in a typical year. Lower is calmer | – | 38.1%category avg 15.8% |
| Worst fallThe biggest drop from a peak in 10 years. Lower is better | −11.4%Bestcategory avg −25.5% | −44.8%category avg −25.5% |
| Best 12 monthsIts strongest year | – | 279.5% |
| Worst 12 monthsIts weakest year | – | -33.6% |
| Odds of a gainShare of all 1-year holding periods that ended in profit | – | 86% |
| Cost and sizeThe fee comes out of your returns every year, whether the fund does well or not. | ||
| Expense ratioYearly fee. Lower keeps more for you | – | 1.06% |
| Fund sizeMoney managed (AUM). Neither better nor worse | ₹436 Cr | ₹1,147 Cr |
| Minimum SIPSmallest monthly amount | ₹100 | – |
| Lock-inTime before you can withdraw | None | None |
“Best” is not a recommendation: a fund that returned more usually took more risk to do it.
Which one fits you?
There is no best fund, only a better fit for what you need the money to do.
AInvesco India Pharma and Healthcare Fund
Might suit you if…
- a smoother ride matters more to you than the top return
BNippon India Taiwan Equity Fund
Might suit you if…
- you prefer its fund house or approach. On these numbers it is not the stand-out on any one measure